Innovative ETFs ChannelGreater Regulatory Scrutiny Could Weigh on Biotech ETFsBy Max ChenMarch 24, 2021
Beyond Basic Beta ChannelBiotech Shined with Vaccines. It Can Do It Again with ‘BBH’By Ben HernandezMarch 3, 2021
Innovative ETFs ChannelIllumina Earnings, Forward Guidance Strengthen Biotech ETFsBy Max ChenFebruary 12, 2021
Innovative ETFs ChannelBiotechnology ETFs Soar on Biogen’s New Alzheimer’s DrugBy Max ChenJanuary 29, 2021
Leveraged & Inverse ChannelUp Over 100% in 2020 and 15% in 2021, ‘LABU’ Isn’t Holding BackBy Ben HernandezJanuary 12, 2021
Innovative ETFs ChannelConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021By Max ChenDecember 31, 2020
Thematic Investing ChannelGet On Board a Growing Biotech Industry With the GNOM ETFBy Ben HernandezDecember 23, 2020
Equity ETF ChannelETF Strategies to Tap into Medical Breakthroughs, Healthcare InnovationsBy Max ChenOctober 30, 2020
Nasdaq Portfolio Solutions ChannelCapitalizing on Today’s Tech: Semiconductors, AI, Robo and Internet FundsBy Max ChenSeptember 8, 2020
Innovative ETFs ChannelAn Outperforming ETF for a Post-Coronavirus Pandemic WorldBy Max ChenAugust 27, 2020
Multi-Factor ChannelHow to Gain Exposure to the Next Generation of HealthcareBy Max ChenAugust 26, 2020
Expert InsightsETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ)By Aaron NeuwirthAugust 20, 2020
Leveraged & Inverse ChannelBiotech Has Been in a Steady Uptrend Even Through Covid-19By Ben HernandezAugust 20, 2020
